{"schema_version":"secwatch.filing_event.v1","accession":"0001645113-26-000023","form_type":"8-K","ticker":"NVCR","cik":"0001645113","company_name":"NovoCure Ltd","filed_at":"2026-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.733168+00:00","generated_at":"2026-05-15T08:50:34.764739+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Novocure PANOVA-4 trial meets primary endpoint; DCR 74.4% vs 48% historical control in mPDAC","bullets":["PANOVA-4 met primary endpoint: DCR 74.4% (N=78) vs 48% historical control (N=431), 1-sided p<0.001.","Secondary endpoints: ORR 34.6% (95% CI 24.2%-46.2%), median OS 9.7 months (95% CI 7.9-12.7 months).","TTFields therapy with atezolizumab and gem/nab-pac well-tolerated; safety consistent with prior studies.","Novocure plans to present further PANOVA-4 data at a future scientific forum."],"urls":{"canonical":"https://secwatch.observer/filing/0001645113-26-000023","json":"https://secwatch.observer/filing/0001645113-26-000023.json","markdown":"https://secwatch.observer/filing/0001645113-26-000023.md","text":"https://secwatch.observer/filing/0001645113-26-000023.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645113/000164511326000023/0001645113-26-000023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645113/000164511326000023/nvcr-20260326.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:50:34.764739+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}